MAP2K7 and plexiform neurofibroma: Several other MEK inhibitors (binimetinib, mirdametinib, trametinib) and the tyrosine kinase inhibitor cabozantinib are also being investigated as medical therapies for NF1-related plexiform neurofibromas [1,18].